Last reviewed · How we verify
NCT00742144
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
Phase 1 trial testing ofatumumab in Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular in 6 participants. Completed in 18 November 2009.
18 November 2009
Quick facts
| Lead sponsor | GlaxoSmithKline |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 6 |
| Start date | 19 September 2008 |
| Primary completion | 18 November 2009 |
| Estimated completion | 18 November 2009 |
| Sites | 3 locations across Japan |
Drugs / interventions tested
- ofatumumab (OFATUMUMAB) — full drug profile →
Conditions studied
- Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular — all drugs for Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular →
Sponsor
GlaxoSmithKline — full company profile →
Who can join
Adults 20 to 79, any sex, with Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label study to evaluate safety, tolerability, efficacy and PK profile of ofatumumab monotherapy in Japanese follicular lymphoma (FL) or chronic lymphocytic leukemia (CLL) patients. subject will receive ofatumumab 8 weekly infusions.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Ofatumumab.
Zhang B. · · 2009 · cited 55× · PMID 20068404 · DOI 10.4161/mabs.1.4.8895 -
Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Ogura M, Hatake K, Tobinai K, Uchida T, et al · · 2013 · cited 10× · PMID 23456745 · DOI 10.1093/jjco/hyt022
Verify or expand the search:
- PubMed search for NCT00742144
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ofatumumab
Trials testing the same drug.
- NCT06551519 — A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofil · recruiting
- NCT06251986 — A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Mult · completed
- NCT06157086 — Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France · active not recruiting
- NCT06121349 — WOE of Anti-CD20 Therapies · completed
- NCT05627271 — The 'Wearing Off' Effect of DMT · completed
Other GlaxoSmithKline trials
Trials by the same sponsor.
- NCT07569081 — A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflam · Phase 2, PHASE3 · not yet recruiting
- NCT07406347 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose · Phase 1 · not yet recruiting
- NCT07286266 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEH · Phase 3 · not yet recruiting
- NCT07286331 — A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer (BEHOLD-E · Phase 3 · not yet recruiting
- NCT07406334 — A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00742144 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by GlaxoSmithKline
- Last refreshed: 17 November 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00742144.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing